SAHPRA (South Africa)

SAHPRA (South African Health Products Regulatory Authority) is South Africa's national health-products regulator established 1 February 2018 as a Section 3A public entity under the Medicines and Related Substances Act 101 of 1965 (as amended by Act 14 of 2015). SAHPRA succeeded the Medicines Control Council (MCC), which had operated as an internal structure of the National Department of Health since 1965. The transition from MCC to SAHPRA was a deliberate institutional reform intended to address the chronic backlog of medicines registration applications that had accumulated under the MCC (estimated at 16,000+ pending applications at the transition point), to improve regulatory throughput, to enhance scientific independence + accountability + to position South Africa as a credible regional + international regulator.

SAHPRA's governance + structure:

• SAHPRA Board — appointed by the Minister of Health under the Medicines Act; provides governance + strategic direction; chaired by an independent non-executive chairperson.
• Chief Executive Officer (CEO) — appointed by the Board; chief executive responsible for SAHPRA operations + reporting to the Board + ultimately to the Minister.
• Medicines Evaluation + Registration Branch — drug + biological + biosimilar + vaccine registration; complementary medicines registration.
• Medical Devices + IVDs Branch — medical-device + IVD registration + post-market surveillance.
• Inspections + Licensing Branch — GMP + GDP + GLP inspections of South African + foreign manufacturing + distribution facilities; pharmacy + wholesale licensing.
• Clinical Trials Branch — clinical-trial authorisation + GCP inspection.
• Vigilance + Risk Management Branch — pharmacovigilance + materiovigilance + post-market surveillance + risk communication.
• Veterinary Medicines + Complementary Medicines Branch — veterinary + complementary medicines registration.
• Regulatory Compliance Branch — falsified-medicines enforcement + Schedule 5/6/7 controlled substances + cannabis regulation.
• Corporate Services — finance, HR, IT, legal, communications.
• Headquartered in Pretoria with regional inspection footprint covering Gauteng, Western Cape, KwaZulu-Natal, Eastern Cape + other provinces.

SAHPRA's regulatory mandate covers: medicines (chemical, biological, biosimilar, vaccine, generic, herbal, complementary, veterinary) under the Medicines Act + General Regulations; medical devices + IVDs under the Medical Devices Regulations 2017 (GN R1515 of 9 December 2016); clinical-trial authorisation under the Medicines Act + GCP framework; GMP + GDP + GLP inspections; pharmacovigilance + materiovigilance under the Medicines Act + GVP framework; Schedule 5/6/7 controlled substances scheduling + cannabis regulation; radiation-emitting devices regulation; complementary + alternative medicines under the Complementary Medicines framework.

SAHPRA is distinct from + complementary to: the South African National Department of Health (NDoH, which owns broader health policy + the Essential Medicines List + public-sector procurement); the South African Pharmacy Council (SAPC, which regulates pharmacy practice + pharmacist registration + pharmacy premises licensing); the Health Professions Council of South Africa (HPCSA, which regulates medical practice + health professions); the National Health Laboratory Service (NHLS, the public-sector laboratory network); the South African Bureau of Standards (SABS, which sets non-health industrial standards); the Department of Agriculture, Land Reform and Rural Development (DALRRD, which regulates primary agricultural production); + the National Nuclear Regulator (NNR, which regulates nuclear materials alongside SAHPRA radiation-emitting devices regulation).

Legal foundations are the Medicines and Related Substances Act 101 of 1965 (as amended by Act 14 of 2015), the Medical Devices Regulations 2017 (GN R1515 of 9 December 2016), the General Regulations under the Medicines Act, the Complementary + Alternative Medicines Regulations, the Veterinary Medicines Regulations + a substantial body of SAHPRA guidelines + circulars implementing the framework.

SAHPRA international engagement: WHO Maturity Level 3 (ML3) for medicines + vaccines achieved October 2022; designated WHO-Listed Authority (WLA) for medicines + vaccines; PIC/S Member since January 2007 (as MCC, continuing under SAHPRA); ICH Observer; active AUDA-NEPAD AMRH + African Medicines Agency (AMA) participant; SADC ZAZIBONA initiative lead; ICMRA active member; WHO PQ Collaborative Registration Procedure (CRP) Reference Authority for SADC region.

The MCC to SAHPRA transition is the most substantial South African pharmaceutical regulatory reform since the original 1965 Medicines Act. Understanding what changed is essential to working with SAHPRA today.

• MCC (1965-2018) — Medicines Control Council operated as an internal structure of the National Department of Health; council members appointed by Minister of Health; secretariat staffed by NDoH; scientific committees populated by external experts; chronic resource + capacity constraints; backlog of 16,000+ pending medicines registration applications by 2018.
• SAHPRA (2018-present) — autonomous Section 3A public entity reporting to the Minister of Health via the SAHPRA Board; CEO + executive accountable to Board; expanded staffing + dedicated regulatory + inspection + pharmacovigilance branches; substantially expanded budget + cost-recovery via SAHPRA fee structure.
• Backlog Clearance Programme — SAHPRA launched 2019 + completed 2022; cleared the ~16,000 MCC-inherited backlog of pending medicines registration applications through a combination of dedicated backlog teams + reliance pathways + simplified renewal procedures + voluntary withdrawal of long-pending applications.
• Cost-recovery fee structure — SAHPRA operates a substantial cost-recovery fee structure (substantially higher than MCC fees) to fund regulatory throughput improvements + scientific independence + inspection capacity.
• Expanded mandate — SAHPRA mandate explicitly extended to medical devices + IVDs (under Medical Devices Regulations 2017) + cannabis regulation + complementary medicines + radiation-emitting devices.
• Reliance + work-sharing — SAHPRA substantially expanded reliance pathways under WHO PQ CRP + ZAZIBONA + AMRH + bilateral reliance agreements with Health Canada + TGA + Swissmedic + Singapore HSA + others.
• Strengthened pharmacovigilance — SAHPRA Vigilance + Risk Management Branch substantially expanded vs MCC; SAEFVIC (Surveillance of Adverse Events Following Vaccinations in Children) + Med-Safety mobile app + active pharmacovigilance + risk communication.
• Strengthened inspection capacity — SAHPRA Inspections + Licensing Branch substantially expanded vs MCC; foreign-manufacturer inspection programme + PIC/S Member full participation + ZAZIBONA joint-inspection cooperation.
• WHO ML3 achievement (October 2022) — SAHPRA achieved WHO Maturity Level 3 for medicines + vaccines + became designated WHO-Listed Authority (WLA), substantially elevating South Africa's international regulatory standing.
• Strategic Plan 2023-2028 — published 2023; sets out SAHPRA ambitions including ML4 progression + expanded WLA scope + AMA Reference Authority role + advanced reliance pathways.

South African pharmaceutical regulation operates under the Medicines and Related Substances Act 101 of 1965 (as amended), a layered framework of primary legislation, regulations + SAHPRA guidelines:

• Medicines and Related Substances Act 101 of 1965 — primary legislation; defines medicines + Scheduled Substances (S0 through S7) + establishes SAHPRA + provides for registration + manufacture + import + export + distribution + labelling controls.
• Medicines and Related Substances Amendment Act 14 of 2015 — established SAHPRA as autonomous Section 3A public entity to succeed MCC; commenced 1 February 2018.
• General Regulations under the Medicines Act — detailed regulations on medicines registration, manufacture, distribution, labelling, advertising, scheduling + clinical trials.
• Medical Devices Regulations 2017 (GN R1515 of 9 Dec 2016) — current medical-device + IVD registration framework; substantively aligned with GHTF / IMDRF principles + EU MDR / IVDR.
• Complementary + Alternative Medicines Regulations — registration + labelling framework for complementary medicines + traditional medicines.
• Veterinary Medicines Regulations — registration + manufacture framework for veterinary medicines.
• South African Good Manufacturing Practice Guide (SA GMP) — substantively aligned with PIC/S GMP Guide + Annexes; mandatory for South African + foreign manufacturers exporting to South Africa.
• South African Good Distribution Practice Guide (SA GDP) — substantively aligned with PIC/S + WHO GDP.
• South African Good Clinical Practice Guidelines — substantively aligned with ICH E6(R2) GCP; mandatory for clinical trials conducted in South Africa.
• South African Pharmacovigilance Guidelines — substantively aligned with WHO + EU GVP Modules; South African-specific reporting via SAHPRA Vigilance + Risk Management Branch + Med-Safety app + SAEFVIC.
• South African Pharmacopoeia — substantively aligned with BP + EP + USP with South African-specific monographs; cross-pharmacopoeia reliance commonly accepted.
• Scheduling (S0-S7) — controlled-substance scheduling framework; S0 (general sales) through S7 (highly restricted including cannabis + selected psychotropics).
• Cannabis regulation — SAHPRA regulates medicinal cannabis cultivation + manufacture + research; substantial framework evolution post-2018 reflecting policy liberalisation.

ZAZIBONA (ZAmbia + ZImbabwe + BOtswana + NAmibia, expanded to include South Africa + Tanzania + Malawi + Mozambique + Eswatini + others) is the Southern African Development Community (SADC) collaborative medicines registration initiative. ZAZIBONA was launched 2013 as a four-country pilot + has progressively expanded into a SADC-wide joint assessment + reliance framework. SAHPRA is the most mature ZAZIBONA Member NRA + frequently acts as Reference Authority for joint assessments.

• Joint assessment of medicines registration dossiers — applicant submits one harmonised dossier to ZAZIBONA Secretariat; joint scientific assessment by Reference Authority + Co-Reference Authority + Concerned Member State input.
• 9-12 month joint assessment timeline (substantially faster than sequential national registration which can take 5-10 years across SADC).
• Reliance on Reference Authority assessment by all participating ZAZIBONA Member States — substantial dossier reduction + reduced inspection burden.
• SADC Member States participating in ZAZIBONA include: South Africa (SAHPRA) + Zambia (ZAMRA) + Zimbabwe (MCAZ) + Botswana (BoMRA) + Namibia (NMRC) + Tanzania (TMDA) + Malawi (PMRA) + Mozambique (ANARME) + Eswatini (Eswatini Ministry of Health) + others.
• ZAZIBONA Secretariat hosted by SADC Secretariat in Gaborone, Botswana with technical secretariat support from participating NRAs on rotating basis.
• WHO + AUDA-NEPAD + Gates Foundation + DFID / UK Aid + EU support — ZAZIBONA has received substantial international support for capacity-building + harmonisation.
• Substantive harmonisation achievements — common Application Form + common Quality Information Summary + common Bioequivalence requirements + harmonised post-approval variations procedure.
• WHO PQ CRP integration — ZAZIBONA increasingly integrates with WHO PQ CRP allowing WHO-PQ-approved products to access ZAZIBONA via CRP + further reducing dossier burden.
• Influence on AMRH + AMA — ZAZIBONA is widely recognised as the most successful African REC-level medicines regulatory harmonisation initiative + serves as a model for AUDA-NEPAD AMRH advancement + African Medicines Agency (AMA) implementation.
• Medical Devices expansion — ZAZIBONA expanded to include medical devices joint assessment 2023+ via the SADC Medical Devices Regulatory Harmonisation Initiative.

South African medical-device + IVD regulation operates under the Medical Devices Regulations 2017 (GN R1515 of 9 December 2016), implementing the Medicines and Related Substances Act 101 of 1965 as amended. The 2017 Regulations replaced the prior ad-hoc framework + introduced risk-based classification, mandatory registration + South African Authorised Representative requirements. Foreign manufacturers must appoint a South African Authorised Representative (SAHPRA AR).

• Risk-based Classification (Class A / B / C / D for medical devices + Class A / B / C / D for IVDs) — substantively aligned with GHTF / IMDRF + EU MDR / IVDR with South African-specific overlay; classification determined by South African Classification Rules.
• Medical Device + IVD Registration Certificate — issued by SAHPRA Medical Devices + IVDs Branch based on technical-file review + South African Authorised Representative designation + South African-language (English + frequently Afrikaans) labelling.
• South African Authorised Representative (SA AR) — South African-resident legal entity required for foreign manufacturers; bears post-market surveillance responsibility + SAHPRA interface.
• ISO 13485:2016 — recognised by SAHPRA as QMS evidence framework; South African-specific overlay required including SAHPRA QMS audit for higher-risk devices.
• MDSAP — South Africa is not currently an MDSAP Participating Regulator + does not formally accept MDSAP audit reports as direct QMS evidence; ISO 13485 + South African-specific overlay required; however, MDSAP reports increasingly accepted as supporting evidence under reliance framework.
• Reliance pathways — SAHPRA accepts CE Mark + FDA 510(k) / PMA + Health Canada + TGA + Swissmedic + MFDS + PMDA + Japan-approval evidence as supporting evidence under reliance framework; reliance reduces dossier requirements + accelerates review.
• Post-market Surveillance + Materiovigilance — SAHPRA operates medical-device adverse-event reporting; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• South African UDI — SAHPRA has not implemented full UDI equivalent to FDA UDI or EU EUDAMED UDI; transition planning is active; SAHPRA UDI Working Group + IMDRF UDI Working Group engagement.
• Licensing of Manufacturers + Distributors — South African manufacturers + distributors require SAHPRA Establishment Licence in addition to product registration.
• Transitional Period — extensive transitional provisions allowed legacy devices to remain in market during 2017-2022 phase-in; post-2022 fully aligned with Medical Devices Regulations 2017.

SAHPRA achieved WHO Maturity Level 3 (ML3) for medicines + vaccines in October 2022 + was designated a WHO-Listed Authority (WLA) for medicines + vaccines — substantially elevating South Africa's international regulatory standing.

• WHO Global Benchmarking Tool (GBT) — WHO assessment framework for NRA maturity across nine regulatory functions; Maturity Level 3 (Stable, Well-Functioning + Integrated) represents WHO's threshold for designating an NRA as a Reference Authority.
• SAHPRA ML3 for medicines + vaccines (October 2022) — achieved through multi-year institutional development with WHO + AUDA-NEPAD + Gates Foundation + DFID + EU support; positions SAHPRA as a SADC + African regulatory reference authority.
• WHO-Listed Authority (WLA) — successor framework to the WHO Stringent Regulatory Authority (SRA) concept; SAHPRA designated WLA for medicines + vaccines based on ML3 achievement.
• Implications for WHO PQ + reliance — SAHPRA assessment + GMP inspection now formally recognised by WHO PQ + by other African + LMIC NRAs as Reference Authority assessment under reliance frameworks.
• African Medicines Agency (AMA) — AU initiative to create a continental medicines agency; AMA Treaty entered into force November 2021; SAHPRA's ML3 + WLA status positions South Africa as a leading AMA Member State + potential AMA Reference Authority.
• AUDA-NEPAD AMRH (African Medicines Regulatory Harmonisation) — AU programme advancing regulatory harmonisation across African Regional Economic Communities (RECs); SAHPRA is a leading AMRH participant alongside Nigeria, Egypt, Ghana + Tanzania.
• WHO PQ CRP Reference Authority — SAHPRA increasingly serves as WHO PQ CRP Reference Authority for SADC + Southern African region products.
• ML4 ambition — SAHPRA has indicated intention to pursue WHO Maturity Level 4 (Continuous Improvement + Advanced Reliance) for medicines + vaccines as next milestone.
• Vaccine NRA Functions — SAHPRA's WHO ML3 vaccine assessment + lot release + post-marketing surveillance functions substantially expanded post-COVID-19 + Aspen Pharmacare J&J COVID-19 vaccine technology transfer + South African mRNA Vaccine Hub establishment.
• African mRNA Vaccine Hub — SAHPRA is the regulator for the WHO-supported African mRNA Vaccine Hub (Afrigen + Biovac + WHO) advancing African vaccine manufacturing sovereignty.

• WHO Maturity Level 3 + WHO-Listed Authority (October 2022) — SAHPRA designated WLA for medicines + vaccines; Reference Authority for SADC + Southern African region.
• PIC/S Member since January 2007 — SAHPRA (continuing from MCC) is a full PIC/S Member with full GMP-inspection reliance with all PIC/S members; one of the longest-standing African PIC/S Members.
• WHO PQ CRP Reference Authority — SAHPRA is an active WHO PQ Collaborative Registration Procedure Reference Authority for SADC + Southern African region products.
• SADC ZAZIBONA Leadership — SAHPRA is the most mature ZAZIBONA Member NRA + frequently acts as Reference Authority for SADC joint assessments.
• AUDA-NEPAD AMRH — leading participant in African Medicines Regulatory Harmonisation programme alongside Nigeria, Egypt, Ghana + Tanzania.
• African Medicines Agency (AMA) — AU continental medicines agency under AMA Treaty (entered into force November 2021); SAHPRA is a leading AMA Member State + South Africa is a candidate AMA Reference Authority.
• ICH Observer — SAHPRA is an ICH Observer; ICH guidelines extensively referenced in South African regulatory practice; SAHPRA + South African industry have engaged ICH Working Groups.
• IMDRF Affiliate — active engagement on IMDRF Working Groups including UDI + QMS + SaMD; South African Medical Devices Regulations 2017 draws on IMDRF + GHTF principles.
• ICMRA Member — active International Coalition of Medicines Regulatory Authorities participant on pandemic preparedness + supply-chain transparency + reliance.
• Bilateral MoUs — SAHPRA holds MoUs with FDA + EMA + MHRA + Health Canada + TGA + Swissmedic + Singapore HSA + ANVISA + NMPA + MFDS + Egyptian EDA + NAFDAC + Ghanaian FDA + Tanzanian TMDA + many other African + global regulators.
• BRICS pharmaceutical cooperation — South Africa is a BRICS Member State (joined December 2010); SAHPRA engages BRICS regulators (NMPA, ANVISA, CDSCO) on regulatory cooperation + reliance.
• African Vaccine Manufacturing Accelerator (AVMA) — SAHPRA is the regulator for African Vaccine Manufacturing Accelerator + African mRNA Vaccine Hub (Afrigen + Biovac) advancing African vaccine manufacturing sovereignty.
• Gavi + Global Fund + Gates Foundation cooperation — SAHPRA works closely with Gavi (vaccine procurement), Global Fund (HIV / TB / malaria procurement) + Gates Foundation (regulatory strengthening) on regulatory + supply-chain coordination.

• South African Authorised Representative not properly designated — application rejected at SAHPRA intake or post-approval compliance failure.
• South African-specific labelling deficiencies — South African English + Afrikaans labelling + South African Rand pricing-reference + South African PIL + South African Climate Zone IVb stability data requirements.
• SA GMP Guide gaps — applicants assuming EU GMP / PIC/S GMP compliance is sufficient without addressing South African-specific SA GMP elements + SAHPRA-specific clarifications.
• South African climate-zone stability data missing — South African Climate Zone IVb (hot + very humid in coastal KZN + Limpopo + Mpumalanga) stability data required for medicines + biologicals; many EU-only + US-only stability packages insufficient.
• ZAZIBONA collaborative-registration opportunity missed — applicants defaulting to national-South African registration without leveraging ZAZIBONA for multi-country SADC market access.
• WHO PQ CRP eligibility not leveraged — WHO-PQ-approved products eligible for accelerated 90-day CRP review at SAHPRA; missed opportunity for substantial review time + cost reduction.
• Bilateral reliance pathway not leveraged — SAHPRA reliance pathways with FDA + EMA + Health Canada + TGA + Swissmedic + others underutilised.
• Backlog Clearance Programme transition gaps — applications submitted pre-2018 under MCC may have been swept into Backlog Clearance Programme; sponsors must verify application status + may need to resubmit under post-2022 normal procedures.
• SAHPRA fee structure underestimated — SAHPRA cost-recovery fee structure substantially higher than legacy MCC fees; sponsors must plan fee budgets accordingly.
• Variations strategy not planned — Type IA / IB / II variations procedure substantively similar to EU but with South African-specific timelines + fee structure.
• Renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration.
• Section 21 vs registration strategy not optimised — Section 21 Authorisation provides patient access for unregistered medicines but is not a substitute for registration for ongoing commercial supply.
• Scheduling (S0-S7) misclassified — South African scheduling framework specific + can differ from EU + US scheduling; misclassification triggers labelling + dispensing-control gaps.
• Pharmacovigilance reporting gaps — SAHPRA Vigilance + Risk Management Branch reporting requirements substantively similar to EU GVP but with South African-specific format + Med-Safety app + SAEFVIC integration requirements.
• Cannabis regulation complexity — SAHPRA medicinal-cannabis framework has evolved substantially post-2018; sponsors must navigate cultivation + manufacture + research + import licensing alongside Department of Health + Department of Agriculture coordination.

V5 Ultimate provides the operational infrastructure South African + foreign-supplier sites need for the Medicines Act + SA GMP Guide + Medical Devices Regulations 2017 + ZAZIBONA + WHO PQ CRP + SAHPRA readiness.

• SA GMP Guide control framework — PIC/S + EU GMP-aligned controls (clean rooms, aseptic process, environmental monitoring, EU GMP Annex 1 2022 alignment, computerised systems) with ALCOA+ data-integrity + South African-specific SA GMP + SAHPRA-specific elements + South African Climate Zone IVb stability monitoring.
• SAHPRA medicines-registration packaging — South African CTD-aligned dossier structure with SAHPRA Module 1 specifics + South African-specific Module 3 stability + South African PIL + English / Afrikaans labelling + South African Authorised Representative declarations.
• ZAZIBONA collaborative-registration workflow — SADC ZAZIBONA harmonised dossier packaging + Reference Authority + Co-Reference Authority + Concerned Member State workflow + 9-12 month joint assessment + multi-country SADC market access.
• WHO PQ CRP workflow — CRP Recipient packaging with WHO PQ Assessment Report + SAHPRA-specific overlay + reduced dossier + accelerated 90-day review path.
• Bilateral reliance workflow — FDA + EMA + Health Canada + TGA + Swissmedic + MHRA + PMDA + MFDS reliance pathway packaging with reduced dossier + accelerated SAHPRA review.
• South African Authorised Representative workflow — foreign-manufacturer SA AR designation + role-management + South African-specific post-market surveillance + SAHPRA interface.
• South African clinical-trial workflow — SA GCP-aligned site management + South African Ethics Committee approval + SAHPRA CTA submission + South African Pharmacopoeia + cross-pharmacopoeia reliance.
• SAHPRA Vigilance + Risk Management pharmacovigilance — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + South African-specific format + Med-Safety app + SAEFVIC integration.
• Medical-device registration + materiovigilance workflow — Medical Devices Regulations 2017 dossier packaging + Class A-D + IVD Class A-D classification + ISO 13485 + South African Authorised Representative + SAHPRA Establishment Licence + post-market surveillance + materiovigilance.
• SAHPRA Variations + Renewals workflow — Type IA / IB / II classification + 5-year renewal window tracking + SAHPRA procedure packaging.
• Scheduling (S0-S7) management — South African scheduling framework labelling + dispensing-control + Schedule 5/6/7 controlled-substance handling + cannabis-specific regulatory workflow.
• SADC + AMRH + AMA regional bridging — for companies operating across SADC + Africa, V5 surfaces South African + Zambian + Zimbabwean + Botswanan + Namibian + Tanzanian + Malawian + Mozambican + Eswatini + AMRH harmonised dossier-element reuse alongside national-specific extensions.